Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 31,346 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study participants Clear all

Conditions: Acute Viral Respiratory Infection
Interventions: PurInf I Botanical Formulation, PurInf II Botanical Formulation, PurInf III Botanical Formulation, PurCo Botanical Formulation, PurPhl Botanical Formulation, PurClo Botanical Formulation; Drug
Lead sponsor: All Natural Medicine Clinic, LLC; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Caregiver Burnout
Interventions: Caregiver-Support; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Glioma, Recurrent High Grade, Grade 4 Malignant Glioma
Interventions: NST-628; Drug
Lead sponsor: Nader Sanai; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
Interventions: ATV-1601, Placebo; Drug
Lead sponsor: Atavistik Bio, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 9
States / cities: Phoenix, Arizona • San Diego, California • Augusta, Georgia + 6 more

Conditions: Migraine
Interventions: Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Urge Incontinence, Urinary Incontinence, Urge
Interventions: Mirabegron, Tolterodine Tartrate; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 65 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: Cabotegravir 200 mg/mL, CAB >=400 mg/mL, CAB Formulation I, CAB Formulation J, rHuPH20, RPV; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 214 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 3
States / cities: Orlando, Florida • Las Vegas, Nevada • Austin, Texas

Conditions: Stimulant Dependence, Methamphetamine-dependence, Addiction, Drug
Interventions: Transcranial Magnetic Stimulation--DPFC first, MPFC second, Transcranial Magnetic Stimulation--MPFC first, DPFC second; Device
Lead sponsor: Ryan M. Carnahan; Other
Eligibility: 18 Years to 60 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: COVID-19, Vaccine Reaction, COVID-19 Pandemic
Interventions: Moderna Booster Vaccine, Pfizer Booster Vaccine; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 301 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prediabetic State
Interventions: patient health record; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 20 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Drug Abuse
Interventions: Intravenous placebo, Intranasal placebo, Intravenous racemic ketamine, Esketamine 112 mg, Esketamine 84 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Prostate Cancer
Interventions: Decipher Questionnaire; Other
Lead sponsor: GenomeDx Biosciences Corp; Industry
Eligibility: Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Menlo Park, California • Celebration, Florida • New York, New York

Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Minimal Residual Disease, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Interventions: Dasatinib, Imatinib Mesylate, Nilotinib, Ruxolitinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Plaque Psoriasis
Interventions: TAK-279; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 2,099 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 74
States / cities: Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 62 more

Conditions: Advanced Cancer
Interventions: BMS-986258, Nivolumab, rHuPH20; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Iowa City, Iowa + 6 more

Conditions: Peritoneal Carcinomatosis
Interventions: Mitomycin C (MMC), Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC); Drug · Device
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Acquired Immunodeficiency Syndrome, HIV
Interventions: Provider Visit Incentive (PVI), Incentive Choice (IC); Behavioral
Lead sponsor: National Bureau of Economic Research, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Tobacco Use, Smoking, Smoking Cessation
Interventions: Cognitive-Motivational Feedback, Staff Tobacco Quit Line Referral Implementation Support, Consumer Incentives for Immediate Referral to a Tobacco Quit Line; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Osteoporosis, Spinal Cord Injuries
Interventions: Romosozumab, Denosumab; Drug
Lead sponsor: James J. Peters Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: West Orange, New Jersey • The Bronx, New York

Conditions: Hallucinations, Auditory, Psychosis
Interventions: Rivastigmine Transdermal System, Scopolamine, Placebo Patch; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Borderline Personality Disorder
Interventions: Personality-Based Cognitive Behavioral Therapy; Behavioral
Lead sponsor: Shannon E. Sauer-Zavala; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Type 2 Diabetes, HbA1c, Protein Intake
Interventions: PP; Dietary Supplement
Lead sponsor: Skidmore College; Other
Eligibility: 30 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Saratoga Springs, New York

Conditions: Moderate Renal Impairment
Interventions: Enlicitide Chloride; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Hallandale, Florida • Knoxville, Tennessee

Conditions: ALK Fusion-positive Solid or CNS Tumors
Interventions: Alectinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Up to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 7
States / cities: Palo Alto, California • St. Petersburg, Florida • Ann Arbor, Michigan + 4 more

Search by objective public record fields.

Botanical Therapy for Acute Viral Respiratory Infections

Caregiver Support in the Context of Multiple Chronic Conditions

A Study of NST-628 in Recurrent Grade 4 Glioma

Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)

Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine

Treatment of Incontinence Without Memory Problems

A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

Pilot TMS for Methamphetamine Use Disorder

The BOOSTED (Booster Options Or Switching Tested for Effectiveness and Downsides Study) Trial (COVID-19)

Use of Track Health Function of the MyHealthevet Personal Health Record

Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users

Multi-site Decision Impact Study for Decipher

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread

Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors

A Commitment Device for Medication Adherence Among HIV Patients

Salvation Army Tobacco Quit Line Referral Implementation Trial

Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI

Toward a Computationally-Informed, Personalized Treatment for Hallucinations

Five Factor Model Treatment for Borderline Personality Disorder

Daily Protein Pacing Effects on HbA1c in Type 2 Diabetics

A Study of Enlicitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Participants With Moderate Renal Impairment (MK-0616-007)

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors